RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just checking inno offense but apH has been absolute garbge so far this year, i made good money with ACB, EMH and HEXO and reinvested in APH and got in all the way to from 9 to 19s assuming good things are happening. What I got in return was supply issue talks and labor shortage issue instead of a bit pumping.
I understand you are cozy and entered at $2 but for most of us trying to make a few$ and using some margins, it is going badly.
nobody to blame but myself, however, I was not expecting to be bashed by our CEO by talking about supply issues instead of bringing positive information forward like lowest cost per gram etc.
no seat in Vegas to attract new investors, no interviews at US media nothing, no wonder we are nearing cron despite their mediocre numbers
INVSTIGAT0R wrote: Exactly. APH is the best value, period. Greenup, think of it this way: Everyone and their mom knew 3.2 billion for Medreleaf was horrendous, same with 1.1 billion for CMED. Do you really think a giant is going to come along and pay a premium on a company that has only got as big as they are by already paying huge premiums? Technically if Diageo somehow took an equity stake in Aurora they would be paying a premium on top of the HUGE premiums already offered for Medreleaf and CMED. Makes zero sense. That would literally be a pyramid scheme. Industry giants are not that stupid. Aurora is though so they'll just sign a JV and that's it. MAYBE an equity stake at a very small premium best case scenario for Aurora.